Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.

Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F.

Med Res Rev. 2005 Mar;25(2):133-66. Review.

PMID:
15389727
2.

Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels.

Testai L, Bianucci AM, Massarelli I, Breschi MC, Martinotti E, Calderone V.

Curr Med Chem. 2004 Oct;11(20):2691-706. Review.

PMID:
15544470
3.

Drug-induced torsade de pointes: from molecular biology to bedside.

Tamargo J.

Jpn J Pharmacol. 2000 May;83(1):1-19. Review.

4.

Molecular determinants of high-affinity drug binding to HERG channels.

Mitcheson JS, Perry MD.

Curr Opin Drug Discov Devel. 2003 Sep;6(5):667-74. Review.

PMID:
14579516
5.

Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.

Shah RR.

Novartis Found Symp. 2005;266:251-80; discussion 280-5. Review.

PMID:
16050273
6.

[HERG K+ channel, the target of anti-arrhythmias drugs].

Guan FY, Yang SJ.

Yao Xue Xue Bao. 2007 Jul;42(7):687-91. Review. Chinese.

PMID:
17882949
7.

Predicting drug-hERG channel interactions that cause acquired long QT syndrome.

Sanguinetti MC, Mitcheson JS.

Trends Pharmacol Sci. 2005 Mar;26(3):119-24. Review.

PMID:
15749156
8.

The hERG potassium channel and hERG screening for drug-induced torsades de pointes.

Hancox JC, McPate MJ, El Harchi A, Zhang YH.

Pharmacol Ther. 2008 Aug;119(2):118-32. doi: 10.1016/j.pharmthera.2008.05.009. Epub 2008 Jun 18. Review.

PMID:
18616963
9.

Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.

Witchel HJ, Hancox JC.

Clin Exp Pharmacol Physiol. 2000 Oct;27(10):753-66. Review.

PMID:
11022966
10.

Acquired QT interval prolongation and HERG: implications for drug discovery and development.

Finlayson K, Witchel HJ, McCulloch J, Sharkey J.

Eur J Pharmacol. 2004 Oct 1;500(1-3):129-42. Review.

PMID:
15464027
11.

Molecular predictors of drug-induced prolongation of the QT interval.

Dilaveris PE.

Curr Med Chem Cardiovasc Hematol Agents. 2005 Apr;3(2):105-18. Review.

PMID:
15853698
12.

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG.

Cardiovasc Res. 2003 Apr 1;58(1):32-45. Review.

PMID:
12667944
13.

Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.

Calderone V, Testai L, Martinotti E, Del Tacca M, Breschi MC.

J Pharm Pharmacol. 2005 Feb;57(2):151-61. Review.

PMID:
15720777
14.

Prolong QT interval and "torsades de pointes" associated with different group of drugs.

Gongadze N, Kezeli T, Antelava N.

Georgian Med News. 2007 Dec;(153):45-9. Review.

PMID:
18250496
15.

QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.

Briasoulis A, Agarwal V, Pierce WJ.

Cardiology. 2011;120(2):103-10. doi: 10.1159/000334441. Epub 2011 Dec 13. Review.

PMID:
22156660
16.

Predictive in silico modeling for hERG channel blockers.

Aronov AM.

Drug Discov Today. 2005 Jan 15;10(2):149-55. Review.

PMID:
15718164
17.

TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability).

Hondeghem LM.

Novartis Found Symp. 2005;266:235-44; discussion 244-50. Review.

PMID:
16050272
18.

Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy.

Abriel H, Schl├Ąpfer J, Keller DI, Gavillet B, Buclin T, Biollaz J, Stoller R, Kappenberger L.

Swiss Med Wkly. 2004 Nov 27;134(47-48):685-94. Review.

PMID:
15616901
19.

QT interval prolongation: and the beat goes on.

Jalaie M, Holsworth DD.

Mini Rev Med Chem. 2005 Dec;5(12):1083-91. Review.

PMID:
16375754
20.

Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs.

Durdagi S, Subbotina J, Lees-Miller J, Guo J, Duff HJ, Noskov SY.

Curr Med Chem. 2010;17(30):3514-32. Review.

PMID:
20738248

Supplemental Content

Support Center